Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

This publication reports a prespecified subgroup analysis from the phase 3 COMPASSION-16 trial, which evaluated cadonilimab added to standard therapy in patients with persistent, recurrent, or metastatic cervical cancer.

Key points:

• Primary endpoints: Progression-free survival (PFS, BICR per RECIST v1.1) and overall survival (OS).
• Secondary endpoint: Objective response rate (ORR).

Subgroup analysis:

• Subgroups included: bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), presence of metastatic disease at baseline, platinum use, and age.
• With a median follow-up of 25.6 months, hazard ratios for PFS favored the cadonilimab arm across all evaluated subgroups.
• The addition of cadonilimab was also associated with improved OS in these subgroups.
• ORR was higher with cadonilimab plus standard therapy compared with standard therapy alone (as a secondary endpoint), consistent with the overall trial findings.

Clinical takeaway:

The benefits of cadonilimab in PFS and OS observed in the main COMPASSION-16 results are maintained across a range of clinically relevant subgroups, supporting its use broadly in patients with persistent, recurrent, or metastatic cervical cancer irrespective of bevacizumab use, prior chemoradiation, PD-L1 status, metastatic burden at baseline, platinum exposure, or age.